Charles Explorer logo
🇬🇧

Lurasidone in the treatment of pharmacoresistant schizoprenia: a case report

Publication at Faculty of Medicine in Hradec Králové |
2021

Abstract

Lurasidone is a serotonin and dopamine receptor antagonist, one of the most recently available antipsychotics in the Czech Republic. It has a minimal effect on physical and metabolic parameters while a significant effectiveness on the symptoms of psychosis is maintained.

This is evidenced by the case report below, which describes a good response to lurasidone in a patient with paranoid schizophrenia and resistence to treatment, including electroconvulsive therapy.